Matteo Bianco
Pieve Emanuele, 20072, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications
Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.
Journal: The British journal of dermatology
Published: May 16, 2026
Pharmacological decongestion: from loop diuretics to sequential nephron blockade
Journal: Giornale italiano di cardiologia (2006)
Published: April 29, 2026
Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study.
Journal: Medicina (Kaunas, Lithuania)
Published: April 13, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.
Journal: Clinical and experimental dermatology
Published: April 12, 2026
Inotropic therapy in outpatients with worsening or advanced heart failure: literature evidence and comparison of Italian management models
Journal: Giornale italiano di cardiologia (2006)
Published: March 25, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Dose escalation and personalization in atopic dermatitis: reply to the real-world study by Demirbaş et al. "Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.".
Journal: The Journal of dermatological treatment
Published: February 06, 2026
Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement.
Journal: Dermatology and therapy
Published: December 19, 2025
JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.
Journal: Medicina (Kaunas, Lithuania)
Published: December 14, 2025
Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
Journal: Revista espanola de cardiologia (English ed.)
Published: December 07, 2025
Digitoxin in heart failure with reduced ejection fraction: back to the future
Journal: Giornale italiano di cardiologia (2006)
Published: November 25, 2025
Risk Stratification Tools in Acute Heart Failure and Their Roles in Personalized Follow-Up.
Journal: Journal of clinical medicine
Published: November 09, 2025
Last Updated: 09/26/2026